86770-67-4Relevant articles and documents
Lipoic acid based core cross-linked micelles for multivalent platforms: Design, synthesis and application in bio-imaging and drug delivery
Huang, Jingsheng,Wu, Fang,Yu, Yunlong,Huang, Haolong,Zhang, Shiyong,You, Jingsong
, p. 4798 - 4802 (2017)
Natural lipoic acid derived small-molecule amphiphiles self-assemble into micelles in water. The presence of numerous disulfides accumulated in the core makes the micelles readily cross-linked to achieve the establishment of core cross-linked micelles (CCMs). Thanks to the inherent biocompatibility, the resulting lipoic acid based CCMs (LA-CCMs) are good multivalent platforms for biomedical applications.
Synthesis and cation-mediated electronic interactions of two novel classes of porphyrin-fullerene hybrids
Baran,Monaco,Khan,Schuster,Wilson
, p. 8363 - 8364 (1997)
The efficient synthesis as well as computational and photophysical studies of two novel classes of prophyrin-C6-hybrids is reported. A new synthetic methodology which can be efficaciously exploited in the construction of structurally unique con
Nucleophilic transformations of azido-containing carbonyl compoundsviaprotection of the azido group
Aimi, Takahiro,Meguro, Tomohiro,Kobayashi, Akihiro,Hosoya, Takamitsu,Yoshida, Suguru
supporting information, p. 6062 - 6065 (2021/06/21)
Nucleophilic transformations of azido-containing carbonyl compounds are discussed. The phosphazide formation from azides and di(tert-butyl)(4-(dimethylamino)phenyl)phosphine (Amphos) enabled transformations of carbonyl groups with nucleophiles such as lithium aluminum hydride and organometallic reagents. The good stability of the phosphazide moiety allowed us to perform consecutive transformations of a diazide through triazole formation and the Grignard reaction.
COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION
-
Page/Page column 51; 52, (2021/06/11)
The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.